BioChina Newsletter
Issue: Vol. 12, No. 4
Dec 2019

INSIDE THIS EDITION:

- **BioBusiness in China**
- **Vendor BioBusiness in China**

BioBusiness in China

WuXi Vaccines to Build USD $240M Manufacturing Facility in Ireland – WuXi Biologics recently announced its subsidiary WuXi Vaccines will invest USD $240M to build a new vaccine manufacturing facility in Ireland. The vaccine manufacturing facility will include drug substance manufacturing, drug product manufacturing, and Quality Control labs (QC). The facility, once approved, will be located within the WuXi Biologics Campus adjacent to the "Factory of the Future" biologics drug substance manufacturing facility, and is scheduled for commercial manufacturing in 2021. *Source: WuXi Company Website, Nov 2019*

BeiGene Completes Phase I Construction of Biologics Production Facility - BeiGene recently completed Phase I construction of its biologics production facility in Guangzhou, China after 2 years. The total investment of the facility is USD $328 MIL and has 8,000L in capacity. BeiGene will use the facility to manufacture its anti PD-1 therapeutic Tislelizumab, which is expected to serve both domestic and global markets. *Source: Caijing Net, Sep 27th, 2019*

CMAB Announces Positive Opinion in External European Quality Audit - CMAB Biopharma, a pure-play contract development and manufacturing organization specializing in the production of mammalian cell-derived biologic products, recently announced the co. received a positive opinion, after a comprehensive and thorough inspection, in an external European quality audit conducted by Parexel International Co. The audit was to confirm that CMAB's quality standards are in line with European GMP. *Source: CMAB Biopharma Company Website, Nov 2019*

Zhixiang Jintai Completes Phase I Construction of mAb Facility - Chongqing-based Zhixiang Jintai, dedicated to mAb therapeutics development, recently announced it completed Phase I construction of its mAb production facility. Started in Aug. 2017 with 12 mAb production lines, its projected 10-15 mAb drugs will be manufactured and launched from this facility in the next 8-10 years. At current stage, the co. has 3 mAb in its pipeline, with anti-EGFR mAb and anti PD-L1 at phase I and anti-IL-17 mAb phase I complete. *Source: Qianlong Net, Nov 2019*

Ruiyang Pharma Completes Major Construction Work of mAb Production Base - Ruiyang Pharma announced it has completed major construction work for its mAb production base in ZiBo, Shandong Province, China. The facility has 4*2000L single use production lines as well as 2*5000L stainless steel bioreactors. When completed the facility will be able to

produce 20 MIL injections of PD-1 and PD-L1 mAb therapeutics, considered to be the highest output of such therapeutics in China. The facility is projected to be in pilot operation by the end of 2020. *Source: Interview with Dazhong Net, Zibo Channel, July 2019*

Hualan Biologics Signs Agreement with Xinxiang Municipal Govt for mAb Facility - Hualan Biologics signed an agreement with the Xinxiang municipal govt. to build an mAb therapeutics facility in Xinxiang, Henan Province, China. The co. is the first flu vaccine maker with WHO pre-qualification in China. *Source: Xinxiang Municipal Government, Nov 15th, 2019*

North China Pharma Plans a New mAb Production Site - North China Pharma started a bidding process for its mAb production facility on Feb, 2019. The facility is based in Shijiazhuang, Hebei province, China. *Source: Bidding and Procurement Net, Feb 2019*

GenScript Biotech Corp. opens CMO - GenScript Biotech Corp. opened one of the largest CMO facilities in Zhenjiang, Jiangsu, China, to manufacture preclinical and clinical supplies. *Source: PRNewswire, July 17, 2019*

Great Bay Bio CMO opens in Hong Kong - Great Bay Bio, a new CMO, recently opened in Hong Kong, and will offer early stage and preclinical CMC development services. *Source: Contract Pharma, June 18, 2019*

WuXi Biologics Expands Facility - WuXi Biologics is expanding its Wuxi, China, facilities with the addition of a new antibody-drugs and other conjugation commercial manufacturing facility. *Source: Pharma's Almanac, June 27, 2019*

Lion TCR Pte. Ltd. is constructing 5,000 sq. meters of cellular therapies manufacturing and research facilities in Singapore with assistance from the Dalian Lvshun District Govt. *Source: Lion TCR press release, Aug. 9, 2019*

Vendor BioBusiness in China

Thermo Fisher Opens Customer Solution Center in Shanghai - Thermo Fisher Scientific recently opened its Pharma and Biopharma Customer Solution Center in Shanghai. This is another strategic move after the company upgraded its clinical trial (Suzhou) facility earlier this year. The center will dedicate its efforts to chromatography and mass spectrometry-based analysis process and solution to facilitate speedy drug development and clinical translation, and provide technical support and training services for clients. *Source: Thermo Fisher Website, Nov 2019*

SCIEX Signs Strategic Agreement with Novogene - SCIEX recently announced it signed a strategic collaboration agreement with Beijing-based Novogene, a leader in genetic engineering products and services in China. The two parties will start full-range collaboration in precise metabonomics analysis. SCIEX starts collaboration with Novogene in 2019, which is part of its in China for China strategy. The collaboration will rely on SCIEX's strength in mass spectrum analysis and service for scientific research. *Source:China Instrument News, Oct 2019*

Thermo Fisher Upgrades Clinical Service Facility in Suzhou - Thermo Fisher announced it has completed upgrading its clinical service (Suzhou) facility. After upgrading, the 7,000 sq. mt. Suzhou facility will be Thermo Fisher's largest clinical service facility in Asia-Pacific, providing supply chain and transportation service for clients. Thermo Fisher also announced a strategic collaboration with Nanjing-based Frontier Biotech to develop 3BNC117, an antibody against HIV. Using its manufacturing base in St Louis, Missouri, USA, the co. will be the exclusive manufacturing partner of 3BNC117. *Source: Thermo Fisher Website, Sep 2019*

Thermo Fisher Announces Strategic Alliance with GenScript - Thermo Fisher announced a strategic alliance with Nanjing-based GenScript, a CDMO in China. The two companies will start collaborating in the life science and biopharmaceutical sector. Thermo Fisher will provide a one stop solution for mAb therapeutics development from early stage development to manufacturing, while providing support in upgrading of GenScript's existing mAb platform. *Source: Thermo Fisher Website, August 2019*

Thermo Fisher Opens BioScience Customer Exploration Center in Shanghai - Thermo Fisher recently announced the opening of its first BioSciences Customer Exploration Center in Shanghai, China The center has two core labs (cell lab and bio lab) and will provide complete process solutions covering cell and protein analysis as well as protein/nucleic acids engineering. *Source: Xinji China, August 2019*

China Top 60 Biopharmaceutical Manufacturing Directory, 2nd Ed.

The completely updated, comprehensive Top 60 Directory provides detailed profiles of China biopharma facilities, including information on their capacity, history, products, scale, management, business focus, products, R&D, business and partnering strategies, strengths and weaknesses, and future objectives. **For additional information, click here.**

Top 60 Biopharmaceutical Facilities in China Directory allows readers to keep up-to-date on new and existing biopharmaceutical facilities as the industry continues to grow and expand.

Advances in Biopharmaceutical Technology in China, 2nd Ed.

China's Emergence in Global Biopharma Manufacturing: Progress and Trends in Chinese Biopharma Industry; Overview, Developments in Biologics, Biosimilars, and Global Expansion. **For additional information, click here.**

The **2nd Ed. Advances in Biopharmaceutical Technology in China** is a unique, peer-reviewed study that incorporates the work from dozens of authoritative sources, as well as the findings from the first edition, which was completed in 2006.

Click here for the Table of Contents PDF

Questions? Call: +1-301-921-5979 or email info@bioplanassociates.com